Genmab U.S., Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$25.5M
Doctors Paid
6,243
Transactions
16,260
2024 Total
$15.5M
Payment Breakdown by Category
Research$22.0M (86.2%)
Consulting$1.0M (4.1%)
Travel$484,125 (1.9%)
Food & Beverage$465,806 (1.8%)
Royalty/License$8,000 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22.0M | 1,609 | 86.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 357 | 4.4% |
| Consulting Fee | $1.0M | 343 | 4.1% |
| Travel and Lodging | $484,125 | 1,025 | 1.9% |
| Food and Beverage | $465,806 | 12,868 | 1.8% |
| Education | $167,052 | 6 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $161,145 | 50 | 0.6% |
| Grant | $75,000 | 1 | 0.3% |
| Royalty or License | $8,000 | 1 | 0.0% |
Payments by Type
Research
$22.0M
1,607 transactions
General
$3.5M
14,651 transactions
Ownership
$0
2 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | $8.5M | 0 | 463 |
| A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | $2.9M | 0 | 287 |
| Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors | $2.2M | 0 | 111 |
| First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | $1.5M | 0 | 226 |
| A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer. | $1.3M | 0 | 87 |
| A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor | $1.0M | 0 | 284 |
| Multicenter randomized phase II study of epcoritamab for patients with aggressive B-cell lymphomas achieving a partial response after CD19-directed CAR-T therapy | $773,729 | 0 | 1 |
| A Phase 2 Study of Epcoritamab and Lenalidomide (E-Len) in Patients With Previously Untreated Follicular Lymphoma (FL) | $675,588 | 0 | 4 |
| A PHASE 1B/2 OPEN-LABEL TRIAL OF TISOTUMAB VEDOTIN HUMAX-TF-ADC MONOTHERAPY AND IN COMBINATION WITH OTHER AGENTS IN SUBJECTS WITH RECURRENT OR STAGE IVB CERVICAL CANCER | $659,919 | 0 | 87 |
| Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas | $601,927 | 0 | 1 |
| A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma | $360,491 | 0 | 2 |
| A Phase 2 Study of Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a Complete Response with Upfront Chemoimmunotherapy | $322,386 | 0 | 1 |
| Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma. | $295,842 | 0 | 3 |
| An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | $269,227 | 0 | 26 |
| A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer | $222,240 | 0 | 16 |
| A Phase 2 Trial Investigating Epcoritamab in Patients With Previously Treated Waldenstrom Macroglobulinemia (WM) | $195,516 | 0 | 1 |
| A Phase II Trial Evaluating Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | $170,284 | 0 | 1 |
| A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer | $63,938 | 0 | 4 |
| A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer | $18,675 | 0 | 1 |
| A SINGLE ARM, MULTICENTER, INTERNATIONAL TRIAL OF TISOTUMAB VEDOTIN (HUMAX-TF-ADC) IN PREVIOUSLY TREATED, RECURRENT OR METASTATIC CERVICAL CANCER | $750.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Bradley Monk, Md, MD | Gynecologic Oncology | West Palm Beach, FL | $138,705 | $0 |
| Chirag Shah | Gynecologic Oncology | Seattle, WA | $84,222 | $0 |
| Dr. Heidi Godoy, Do, DO | Gynecologic Oncology | Albany, NY | $83,293 | $0 |
| Dr. Scott Jordan, M.d, M.D | Gynecologic Oncology | Fort Lauderdale, FL | $69,118 | $0 |
| Dr. Tara Graff, Do, DO | Medical Oncology | Clive, IA | $65,028 | $0 |
| Dr. Thomas Krivak, Md, MD | Gynecologic Oncology | Pittsburgh, PA | $63,708 | $0 |
| Dr. Dana Chase, M.d, M.D | Gynecologic Oncology | Los Angeles, CA | $60,356 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $58,625 | $0 |
| Leslie Randall, Md, MD | Obstetrics & Gynecology | Fairfax, VA | $54,232 | $0 |
| Courtney Arn, Cnp, CNP | Women's Health | Columbus, OH | $54,034 | $0 |
| Joshua Kesterson, Md, MD | Obstetrics & Gynecology | Newport, PA | $48,358 | $0 |
| John Chan, Md, MD | Obstetrics & Gynecology | San Francisco, CA | $47,161 | $0 |
| Tiffany Redfern, M.d, M.D | Obstetrics & Gynecology | Fort Worth, TX | $45,076 | $0 |
| Mark Shahin, Md, MD | Gynecologic Oncology | Hershey, PA | $41,614 | $0 |
| Kimberly Halla, Fnp-C, FNP-C | Family | Gastonia, NC | $38,316 | $0 |
| Dr. Mark Fesler, Md, MD | Internal Medicine | Saint Louis, MO | $36,208 | $0 |
| Dr. Tycel Phillips, M.d, M.D | Internal Medicine | Duarte, CA | $35,015 | $0 |
| Lorenzo Falchi, M.d, M.D | Medical Oncology | New York, NY | $34,451 | $0 |
| Joshua Brody, M.d, M.D | Hematology & Oncology | New York, NY | $32,520 | $0 |
| Raghuveer Ranganathan, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $31,970 | $0 |
| Andrew Ip, M.d, M.D | Hematology | Hackensack, NJ | $29,735 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $29,221 | $0 |
| Dr. Jonathan Abbas, Md, MD | Hematology & Oncology | Nashville, TN | $29,209 | $0 |
| Dr. Suzanne Fanning, D.o, D.O | Hematology & Oncology | Greenville, SC | $27,301 | $0 |
| Mrs. Gabriella Magarelli, Rn, Acnp-Bc, Ocn, RN, ACNP-BC, OCN | Acute Care | Hackensack, NJ | $26,939 | $0 |
About Genmab U.S., Inc.
Genmab U.S., Inc. has made $25.5M in payments to 6,243 healthcare providers, recorded across 16,260 transactions in the CMS Open Payments database. In 2024, the company paid $15.5M. The top product by payment volume is Epkinly ($13.7M).
Payments were distributed across 112 medical specialties. The top specialty by payment amount is Gynecologic Oncology ($691,180 to 182 doctors).
Payment categories include: Food & Beverage ($465,806), Consulting ($1.0M), Research ($22.0M), Travel & Lodging ($484,125), Royalties ($8,000).
Genmab U.S., Inc. is associated with 1 products in the CMS Open Payments database.